Nexstim Receives Order for Two NBS 6 Systems from Distributor


Press release, Helsinki, 21 December 2023 at 9 AM (EET)

Nexstim Receives Order for Two NBS 6 Systems from Distributor

Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”) announces having received an order for two NBS 6 systems from a distributor company.


Nexstim released the NBS 6 system earlier in 2023 in the EU and the United States. Developed in collaboration with Nexstim’s customers, the NBS 6 system makes the company’s clinically established, e-field navigated TMS (transcranial magnetic stimulation) technology more user-friendly than ever before. The NBS 6 system is currently approved for the treatment of major depressive disorder (MDD) in the United States and EU as well as for the treatment of chronic neuropathic pain in the EU. More information on the NBS 6 system is available on Nexstim’s website at

Mikko Karvinen, CEO of Nexstim, comments: “The release of the NBS 6 system is a result of years of committed work from the Nexstim team. The NBS 6 software is embedded and easy to use, and the modular configuration of the system enables both tailoring the features of the system to the customer’s needs, as well as the inclusion of additional features to respond to future research and healthcare needs. We are really happy to see that key strategic objective of releasing the NBS 6 system this year 2023 has now recently realized in multiple customer and distributor orders.”

Further information is available on the website, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
[email protected]

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit


Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.